10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-Complement Factor D Reference Antibody (lampalizumab)

Recombinant Antibody
Catalog # APR10146

Specification

Anti-Complement Factor D Reference Antibody (lampalizumab) - Product Information

Application	**FC, Kinetics, Animal Model**
Primary Accession	P00746
Reactivity	**Human, Rabbit**
Clonality	**Monoclonal**
Isotype	**IgG1**
Calculated MW	**143.8 KDa**

Anti-Complement Factor D Reference Antibody (lampalizumab) - Additional Information

Target/Specificity
Complement Factor D

Endotoxin
< 0.001EU/ μg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-Complement Factor D Reference Antibody (lampalizumab) - Protein Information

Name CFD (HGNC:2771)

Synonyms DF, PFD

Function
Serine protease that initiates the alternative pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:21205667, PubMed:22362762, PubMed:6769474, PubMed:874324, PubMed:9748277). In contrast to other complement pathways (classical, lectin and GZMK) that are directly activated by pathogens or antigen-antibody complexes, the alternative complement pathway is initiated by the spontaneous hydrolysis of complement C3 (PubMed:<a

href="http://www.uniprot.org/citations/21205667" target="_blank">21205667, PubMed:22362762, PubMed:6769474, PubMed:874324). The alternative complement pathway acts as an amplification loop that enhances complement activation by mediating the formation of C3 and C5 convertases (PubMed:21205667, PubMed:22362762, PubMed:6769474, PubMed:874324). Activated CFD cleaves factor B (CFB) when the latter is complexed with complement C3b, activating the C3 convertase of the alternative pathway (PubMed:21205667, PubMed:6769474, PubMed:874324, PubMed:9748277).

Cellular Location
Secreted

Anti-Complement Factor D Reference Antibody (lampalizumab) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Anti-Complement Factor D Reference Antibody (lampalizumab) - Images



Anti-Complement Factor D Reference Antibody (lampalizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



The purity of Anti-Complement Factor D Reference Antibody (lampalizumab)is more than 99.38% ,determined by SEC-HPLC.



Immobilized human Complement Factor D, Fc at 2 μg/mL can bind Anti-Complement Factor D Reference Antibody (lampalizumab)，EC50=0.02371 μg/mL